Uncovering undetected hypoglycemic events

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 57-74

  Unger, Jeff ^a  

^a Catalina Research Institute California   (United States)

Author keywords

Hypoglycemia; Insulin analogs; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIPHASIC INSULIN; EXENDIN 4; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; PLACEBO; SHORT ACTING INSULIN; SULFONYLUREA;

ALGORITHM; AUTONOMIC DYSFUNCTION; AWARENESS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INTERMETHOD COMPARISON; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT EDUCATION; REVIEW; RISK REDUCTION; TREATMENT PLANNING;

EID: 84859779086     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S29367     Document Type: Review

References (76)

1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002; 45(7):937-948.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
3. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15): 1410-1418.
4. Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. Alexandria, VA: American Diabetes Association; 2009.
5. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902-1912.
6. Unger J, Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med. 2011;123(4):81-91.
7. Unger J, Parkin C. Recognition, prevention, and proactive management of hypoglycemia in patients with type 1 diabetes mellitus. Postgrad Med. 2011;123(4):71-80.
8. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245-254.
9. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249.
10. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 Suppl 1:S11-S63.
11. US Food and Drug Administration. Guidance for industry: diabetes mellitus-developing drugs and therapeutic biologics for treatment and prevention. Rockville, MD: US Food and Drug Administration; 2008.
12. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176-1180.
13. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749-755.
14. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-1147.
15. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665-671.
16. Janssen MM, Snoek FJ, de Jongh RT, Casteleijn S, Deville W, Heine RJ. Biological and behavioural determinants of the frequency of mild, biochemical hypoglycaemia in patients with type 1 diabetes on multiple insulin injection therapy. Diabetes Metab Res Rev. 2000; 16(3):157-163.
17. Fisher M. Hypoglycaemia in patients with type 2 diabetes: minimising the risk. Br J Diabetes Vasc Dis. 2010;10:35-41.
18. McNay EC, Cotero VE. Mini-review: impact of recurrent hypoglycemia on cognitive and brain function. Physiol Behav. 2010;100(3): 234-238.
19. Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab. 2005;7(5):493-503.
20. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565-1572.
21. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
22. Gerstein HC, Miller ME, Genuth S, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828.
23. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298.
24. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Br Med J. 2010;340:b4909.
25. Schopman JE, Geddes J, Frier BM. Frequency of symptomatic and asymptomatic hypoglycaemia in type 1 diabetes: effect of impaired awareness of hypoglycaemia. Diabet Med. 2011;28(3):352-355.
26. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68(1):10-15.
27. Gonder-Frederick LA, Schmidt KM, Vajda KA, et al. Psychometric properties of the Hypoglycemia Fear Survey-II for adults with type 1 diabetes. Diabetes Care. 2011;34(4):801-806.
28. Tupola S, Rajantie J, Akerblom HK. Experience of severe hypoglycaemia may influence both patient's and physician's subsequent treatment policy of insulin-dependent diabetes mellitus. Eur J Pediatr. 1998;157(8):625-627.
29. Zhang Y, Wieffer H, Modha R, Balar B, Pollack M, Krishnarajah G. The burden of hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives. J Clin Outcomes Manage. 2010;17(12):547-557.
30. Frier BM. The economic costs of hypoglycaemia. Br J Diabetes Vasc Dis. 2011;11 Suppl 1:10-12.
31. Harris SB, Leiter LA, Yale J-F, Chaisson J-L, Kleinstiver P, Sauriol L. Out of pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes. 2007;31(1):25-33.
32. Curkendall SM, Zhang B, Lenhart GM, et al. Impact of hypoglycemia events on short-term disability and absenteeism in patients with type 2 diabetes [Abstract]. Diabetes. 2011;60 Suppl 1: A549-A573.
33. Unger J. Insulin initiation and intensification in patients with type 2 diabetes mellitus for the primary care physician. Diabetes Metab Syndr Obes. 2011;4:253-261.
34. California Healthcare Foundation/American Geriatrics Society. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(Suppl 5):S265-S280.
35. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171(4):362-364.
36. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-986.
37. Hoelzel W, Miedema K. Development of a reference system for the international standardization of HbA1c/glycohemoglobin determinations. J Int Fed Clin Chem. 1996;9(2):62-67.
38. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274.
39. Polonsky WH, Fisher L, Schikman CH, et al. A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. Diabetes Technol Ther. 2011;13(8):797-802.
40. Rodbard HW, Schnell O, Unger J, et al. Use of an automated decision support tool optimizes clinicians ability to interpret and appropriately respond to structured self-monitoring of blood glucose data. Diabetes Care. 2012 Feb 16 [Epub ahead of print].
41. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. 1998;338(23): 1657-1662.
42. Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T. Evaluation of a self-management-based patient education program for the treatment and prevention of hypoglycemia-related problems in type 1 diabetes. Patient Educ Couns. 2006;60(2):228-234.
43. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007;1(4):540-548.
44. Brunton S. Safety and effectiveness of modern insulin therapy: the value of insulin analogs. Consultant. 2009;Suppl:S13-S19.
45. Clore JN, Thurby-Hay L. Basal insulin therapy. Curr Diab Rep. 2004;4(5):342-345.
46. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10): 1415-1434.
47. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-1620.
48. Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. September 27, 2011. [Epub ahead of print.]
49. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661-665.
50. Heise T, Hovelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H. Insulin degludec: two-fold longer half-life and more consistent pharmacokinetic profile than insulin glargine. Diabetologia. 2011; 54 Suppl 1:S425.
51. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec [Abstract]. Diabetes. 2011;60 Suppl 1A:LB12.
52. Heller S, Francisco AM, Pei H, Russell-Jones D. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes [Abstract]. Diabetes. 2011;60 Suppl 1:A19.
53. Garber AJ, King AB, Francisco A, Endahl LA, Hollander PA. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes [Abstract]. Diabetes. 2011;60 Suppl 1:A20.
54. Meneghini L, Atkin S, Bain S, et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes [Abstract]. Diabetes. 2011; 60 Suppl 1A:LB10-LB11.
55. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;2:CD003287.
56. Home PD, Lindholm A, Riis A. Insulin aspart versus. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17(11): 762-770.
57. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group. Diabetes Care. 1999;22(10): 1607-1611.
58. Yamada S. Insulin glulisine in the management of diabetes. Diabetes Metab Syndr Obes. 2009;2:111-115.
59. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910-1914.
60. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 versus. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19(5):393-399.
61. Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15(8):496-502.
62. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30(5):1044-1048.
63. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669-674.
64. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010;12(4):249-255.
65. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011;34(11):2403-2405.
66. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care. 2011;34(9):2023-2025.
67. Pearson TL. Practical aspects of insulin pen devices. J Diabetes Sci Technol. 2010;4(3):522-531.
68. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10): 1712-1725.
69. Spiller HA, Borys DJ, Ryan ML, Sawyer TS, Wilson BL. Unintentional therapeutic errors involving insulin in the ambulatory setting reported to poison centers. Ann Pharmacother. 2011;45(1):17-22.
70. Pfutzner A. FlexPen for the delivery of insulin: accuracy, injection force and patient preference. Expert Rev Med Devices. 2009;6(2):115-123.
71. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33(5):511-527.
72. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
73. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31(7):1511-1523.
74. Unger J, Nadeau DA. Def ining the role of incretin mimetic therapy in the management of type 2 diabetes. J Fam Pract. 2007; 56(Suppl 12):S4-S10.
75. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-962.
76. Misurski D, Lage MJ, Fabunmi R, et al. A comparison of costs among patients with type 2 diabetes who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy. 2009;7(4):245-254.